Understanding how Staphylococcus aureus bacteria colonises skin affected by atopic dermatitis could lead to new treatments that help prevent the spread of antibiotic resistance, say scientists.
List view / Grid view
Researchers have engineered F12, a lysin-based antibacterial drug, to have limited negative side-effects and so it can be administered repeatedly without loss of efficacy.
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
A new vaccine against the Staphylococcus aureus infection has proven effective in experiments with mice, with an 80 percent survival rate.